Hutchison China Meditech Ltd (HCM)
HCM Share PerformanceMore
|52 week high||4,580.00 16/10/17|
|52 week low||1,810.00 25/10/16|
|52 week change||2,655.00 (145.88%)|
|4 week volume||263,474 22/09/17|
Latest News« previous» nextMore
17/10/2017 - 09:54 StockMarketWire
Hutchison China Meditech has announced that savolitinib - the lung cancer drug being developed in collaboration with As...
17/10/2017 - 07:00 RNS
RNS Number: 7831T Hutchison China Meditech Limited 17 October 2017 Chi-Med and AstraZeneca's Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET -Amplification - Data for savolitinib in combination with Tagrisso or Iressa presented at World Conference on Lung Cancer- - New data give insights in...
16/10/2017 - 09:05 StockMarketWire
Hutchison China MediTech has reported preliminary clinical activity, safety, and tolerability data of fruquintinib, an inve...
16/10/2017 - 07:00 RNS
RNS Number: 6323T Hutchison China Meditech Limited 16 October 2017 Press Release Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer - Fruquintinib in combination with Iressa (gefitinib) shows promising efficacy and an acceptable safetyprofile- - Further validation of strong potential for use of fruquintinib in co...
12/10/2017 - 07:30 RNS
RNS Number: 4095T Hutchison China Meditech Limited 12 October 2017 Appointment of Director London: Thursday, October 12, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Professor Mok, Shu Kam Tony has been appointed as Independent Non-Executive Director and member of the Technical Committee with...
29/09/2017 - 16:20 Interactive Investor
The annual AIM Awards are almost upon us, so former AIM writer of the year Andrew Hore names the small-cap compa...
29/09/2017 - 07:04 RNS
RNS Number: 2064S Hutchison China Meditech Limited 29 September 2017 Press Release Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting - Data to show potential of savolitinib to treat EGFR-TKI resistance in both Iressa and Tagrisso refractory patients with MET amplification- - Results to further validate Chi-Med's scien...
29/09/2017 - 07:00 RNS
RNS Number: 2058S Hutchison China Meditech Limited 29 September 2017 Press Release Chi-Med Highlights Oral Presentations at CSCO Annual Meeting - Three oral presentations given at CSCO for fruquintinib, savolitinib and theliatinib- - Plenary keynote presentation for FRESCO Phase III trial details analysis showing consistent survival benefit in all key subgrou...
Latest discussion posts More
“Lead article in today's London Evening standard https://www.standard.co.uk/business/anthony-hilton-the-remarkable-tale-of-chimed-s-growth-a3661656.html Mr Hilton has ...”▼
“September's data shows HCM at 10.33% of his growth fund. http://www.slaterinvestments.com/media/108554/slater_growth_fund_a_-_fact_sheet_september_2017.pdf Given it was ...”▼
“when it was what? between 1200 and 2000p? I notice Canaccord, Stifel and Panmure keep upgrading their price targets as the Company smashes them!”▼
Codes & Symbols
|Symbols||HCM, LSE:HCM, HCM.L, HCM:LN, LON:HCM, XLON:HCM|